PST-611 not checked

Eyevensys

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle”In the company’s words, NCT07705568 on ClinicalTrials.gov
Tested for
Geographic Atrophy, Age - Related Macular Degeneration (AMD)
Main trialPhase 2
“The goals of this interventional study are (1) to evaluate the safety and tolerability of multiple doses of PST-611 in men and women over the age of 65 with geographic atrophy secondary to age-related macular degeneration and (2) to assess efficacy of multiple doses of PST-611 by assessing retinal morphology and visual function changes over time. Participants will: * receive one dose every 20 weeks, for a total of 3 doses. * will be followed up for a total of 52 weeks following the first PST-611 dose.”In the company’s words, NCT07705568 on ClinicalTrials.gov

Other drugs for Geographic Atrophy

All 23 drugs for Geographic Atrophy

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Jun 2028 An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy
Phase 1Completed 7 Apr 2026 A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow PST-611

Following is part of Solo: you see every change to PST-611 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in